Cannabinoid Receptor 2 as a potential therapeutic target in Rheumatoid Arthritis

在这项研究中，我们研究了选择性大麻素受体2（CB 2）激动剂对关节炎的治疗作用。免疫组化结果显示，类风湿关节炎（RA）滑膜组织中的巨噬细胞、成纤维细胞样滑膜细胞（FLS）和淋巴细胞均表达CB 2。选择性CB 2激动剂JWH 133抑制TNF刺激的FLS产生IL-6、MMP-3和CCL 2，以及外周血单核细胞的破骨细胞生成。给小鼠II型胶原（CII）诱导的关节炎（CIA）施用JWH 133降低了关节炎评分、炎性细胞浸润、骨破坏和抗CII IgG 1产生。结果表明，选择性CB 2激动剂可能是一种新的治疗RA，抑制FLS，破骨细胞生成和自身抗体产生的炎症介质的生产。

In this study, we investigated therapeutic effects of a selective cannabinoid receptor 2 (CB2) agonist on arthritis. Immunohistochemistry showed that CB2 was expressed on macrophages, fibroblast-like synoviocytes (FLS) and lymphocytes in the synovial tissues from rheumatoid arthritis (RA). JWH133, a selective CB2 agonist, inhibited IL-6, MMP-3 and CCL2 production from TNF-stimulated FLS, and osteoclastogenesis of peripheral blood monocytes. Administration of JWH133 to murine collagen type II (CII)-induced arthritis (CIA) reduced the arthritis score, inflammatory cell infiltration, bone destruction, and anti-CII IgG1 production. The results suggested that a selective CB2 agonist could be a new therapy for RA that inhibits production of inflammatory mediators from FLS, osteoclastogenesis, and autoantibody production.